TrialClinical trialPHN-02962026-10-07 19:00 CT
The Role of Phosphodiesterase Inhibitors in Incretin Secretion
Source · ClinicalTrials.gov: peptide AND aging
TLDR
A ClinicalTrials.gov listing marks as completed a study of how roflumilast and sitagliptin affect blood sugar, insulin, and gut hormones in healthy volunteers aged 21–55. Researchers investigated whether the drugs may increase GLP-1; the provided excerpt contains no results.
01—Key points
- 01The study aimed to better understand GLP-1 and other gut hormones relevant to type 2 diabetes.
- 02Eligibility included healthy volunteers with a BMI below 30.
- 03The listing describes four study visits but provides no findings on hormone changes or blood sugar.
Why it matters Editorial
The study addresses GLP-1 secretion as a potential mechanism relevant to diabetes treatment, but the excerpt does not establish an effect.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.